Safety assessments
TEAEs, hypercalcemia
ADVERSE EVENTS, EVENTS, HYPERCALCEMIA
At prespecified intervals throughout the trial, information on the use of concomitant medications was collected. Serum chemistries, hematology, and 25‐hydroxyvitamin D levels, as well as antibodies against PTH, TransCon PTH, and polyethylene glycol (PEG) were measured. Twenty‐four‐hour urine calcium excretion was also assessed. Clinical events of symptomatic hypo‐ or hypercalcemia were also monitored. Treatment‐emergent adverse events (TEAEs), adverse events of special interest (AESI), and treatment‐emergent serious adverse events (SAEs) were documented by site staff at clinic visits and upon review of participant diaries. The seriousness, severity, and causality of all recorded TEAEs were assessed by the trial investigators. Vasodilatory signs and symptoms were prespecified as AESIs.